Leede Financial Issues Positive Outlook for TSE:ONC Earnings

Oncolytics Biotech Inc. (TSE:ONC) – Research analysts at Leede Financial raised their FY2025 earnings per share (EPS) estimates for shares of Oncolytics Biotech in a research report issued on Monday, March 10th. Leede Financial analyst D. Loe now forecasts that the company will post earnings of ($0.40) per share for the year, up from their previous forecast of ($0.41). The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share. Leede Financial also issued estimates for Oncolytics Biotech’s FY2026 earnings at ($0.41) EPS, FY2027 earnings at ($0.38) EPS, FY2028 earnings at ($0.38) EPS and FY2029 earnings at ($0.13) EPS.

Oncolytics Biotech Stock Performance

TSE:ONC opened at C$0.91 on Thursday. Oncolytics Biotech has a fifty-two week low of C$0.86 and a fifty-two week high of C$2.08. The company has a debt-to-equity ratio of 11.75, a current ratio of 2.99 and a quick ratio of 8.86. The stock has a market capitalization of C$70.14 million, a PE ratio of -2.54 and a beta of 1.35. The business’s 50-day simple moving average is C$1.09 and its 200-day simple moving average is C$1.30.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.